SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir by Singh, K, Rubenstein, K, Callier, V, Shaw-Saliba, K, Rupert, A, Dewar, R, Laverdure, S, Highbarger, H, Lallemand, P, Huang, M-L, Jerome, KR, Sampoleo, R, Mills, MG, Greninger, AL, Juneja, K, Porter, D, Benson, CA, Dempsey, W, El Sahly, HM, Focht, C, Jilg, N, Paules, CI, Rapaka, RR, Uyeki, TM, Clifford Lane, H, Beigel, J, Dodd, LE, Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members